|
2016 Journal Article High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumoursKong, Grace, Callahan, Jason, Hofman, Michael S., Pattison, David A., Akhurst, Tim, Michael, Michael, Eu, Peter and Hicks, Rodney J. (2016). High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 44 (3), 476-489. doi: 10.1007/s00259-016-3527-x |
|
2016 Journal Article THYROPET Study: Is It Biology or Technology That Is the Issue?Pattison, David A. and Hicks, Rodney J. (2016). THYROPET Study: Is It Biology or Technology That Is the Issue?. Journal of Nuclear Medicine, 58 (2), 354-354. doi: 10.2967/jnumed.116.181420 |
|
2016 Journal Article 68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneityChang, Chian A., Pattison, David A., Tothill, Richard W., Kong, Grace, Akhurst, Tim J., Hicks, Rodney J. and Hofman, Michael S. (2016). 68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging, 16 (1) 22. doi: 10.1186/s40644-016-0084-2 |
|
2016 Journal Article Intense focal pituitary FDG uptake due to intravascular large B-cell lymphoma in pyrexia of unknown origin : FDG-Avid Pituitary & Intravascular LymphomaPattison, David A., Hofman, Michael S., Bazargan, Ali, Colman, Peter and Hicks, Rodney J. (2016). Intense focal pituitary FDG uptake due to intravascular large B-cell lymphoma in pyrexia of unknown origin : FDG-Avid Pituitary & Intravascular Lymphoma. American Journal of Hematology, 91 (11), 1167-1168. doi: 10.1002/ajh.24469 |
|
2016 Conference Publication PRELIMINARY RESULTS OF (68)GA EXENDIN-4 PET/CT IMAGING OF NEUROENDOCRINE TUMOURS (NETS)Pattison, D., Kong, G., Messazos, B., Hamblin, P., Fourlanos, S., Lee, M., Michael, M., Hong, E., Eu, P. and Hicks, R. (2016). PRELIMINARY RESULTS OF (68)GA EXENDIN-4 PET/CT IMAGING OF NEUROENDOCRINE TUMOURS (NETS). HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication HIGH EFFICACY FROM A PERSONALISED APPROACH USING Y-90-DOTA-OCTREOTATE SEQUENCED WITH (LU)-L-177-DOTA-OCTREOTATE INDUCTION PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT) FOR BULKY NEUROENDOCRINE TUMOURSKong, G., Callahan, J., Hofman, M., Pattison, D., Akhurst, T., Michael, M., Eu, P. and Hicks, R. (2016). HIGH EFFICACY FROM A PERSONALISED APPROACH USING Y-90-DOTA-OCTREOTATE SEQUENCED WITH (LU)-L-177-DOTA-OCTREOTATE INDUCTION PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT) FOR BULKY NEUROENDOCRINE TUMOURS. HOBOKEN: WILEY-BLACKWELL. |
|
2016 Journal Article A New Theranostic Paradigm for Advanced Thyroid CancerPattison, David A., Solomon, Benjamin and Hicks, Rodney J. (2016). A New Theranostic Paradigm for Advanced Thyroid Cancer. Journal of Nuclear Medicine, 57 (10), 1493-1494. doi: 10.2967/jnumed.116.173534 |
|
2016 Conference Publication Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT)Kong, G., Callahan, J., Hofman, M., Pattison, D., Akhurst, T., Michael, M., Eu, P. and Hicks, R. (2016). Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT). 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona Spain, Mar 09-11, 2016. BASEL: KARGER. |
|
2015 Conference Publication MANAGEMENT OF HYPERTENSIVE CRISIS IN PARAGANGLIOMA-A CASE REPORTJackson, Cheryl, Lingaratnam, Senthil, Michael, Michael and Pattison, David (2015). MANAGEMENT OF HYPERTENSIVE CRISIS IN PARAGANGLIOMA-A CASE REPORT. HOBOKEN: WILEY-BLACKWELL. |
|
2015 Journal Article Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine MalignanciesPattison, David A. and Hofman, Michael S. (2015). Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies. PET Clinics, 10 (4), 461-476. doi: 10.1016/j.cpet.2015.05.005 |
|
2015 Journal Article Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosisPattison, David A., Westcott, James, Lichtenstein, Meir, Toh, H.B., Gunawardana, Dishan, Better, Nathan, Forehan, Simon and Sivaratnam, Dinesh (2015). Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. Nuclear Medicine Communications, 36 (4), 356-362. doi: 10.1097/mnm.0000000000000260 |
|
2015 Conference Publication GA-68 DOTA-OCTREOTATE (GATATE) AND F-18 FLUORODEOXYGLUCOSE (FDG) PET/CT IN THE ASSESSMENT OF PARAGANGLIOMAS AND PHEOCHROMOCYTOMASChang, C. A., Hofman, M., Thompson, M., Pattison, D. and Hicks, R. (2015). GA-68 DOTA-OCTREOTATE (GATATE) AND F-18 FLUORODEOXYGLUCOSE (FDG) PET/CT IN THE ASSESSMENT OF PARAGANGLIOMAS AND PHEOCHROMOCYTOMAS. HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication IMPROVED SURVIVAL OF POOR PROGNOSIS FDG-AVID NEUROENDOCRINE TUMOURS WITH LU-177 OCTREOTATE PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT)Hofman, M. S., Kashyap, R., Kong, G., Akhurst, T., Pattison, D., Eu, P. and Hicks, R. J. (2015). IMPROVED SURVIVAL OF POOR PROGNOSIS FDG-AVID NEUROENDOCRINE TUMOURS WITH LU-177 OCTREOTATE PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT). HOBOKEN: WILEY-BLACKWELL. |
|
2014 Journal Article Enhanced White Adipose Tissue Metabolism in Iatrogenic Cushing's Syndrome With FDG PET/CTPattison, David A., Hofman, Michael S., Lau, Eddie, Ware, Rob and Hicks, Rodney J. (2014). Enhanced White Adipose Tissue Metabolism in Iatrogenic Cushing's Syndrome With FDG PET/CT. The Journal of Clinical Endocrinology & Metabolism, 99 (9), 3041-3042. doi: 10.1210/jc.2013-4090 |
|
2014 Conference Publication STONES, GROANS AND BONESCrowther, M. and Pattison, D. (2014). STONES, GROANS AND BONES. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Journal Article Intracoronary 99m Tc-Sestamibi Single Photon Emission Computed Tomography/Computed Tomography for Preoperative Evaluation of At-Risk MyocardiumPattison, David, Westcott, James, Ajani, Andrew, Antippa, Phillip, Joshi, Subodh, Lui, Elaine, Langenberg, Francesca and Better, Nathan (2013). Intracoronary 99m Tc-Sestamibi Single Photon Emission Computed Tomography/Computed Tomography for Preoperative Evaluation of At-Risk Myocardium. Circulation, 128 (5), 567-570. doi: 10.1161/circulationaha.113.001417 |
|
2013 Journal Article Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelinesCheung, A. S., Pattison, D., Bretherton, I., Hoermann, R., Lim Joon, D., Ho, E., Jenkins, T., Hamilton, E. J., Bate, K., Chan, I., Zajac, J. D. and Grossmann, M. (2013). Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines. Andrology, 1 (4), 583-589. doi: 10.1111/j.2047-2927.2013.00093.x |
|
2013 Conference Publication APPEARANCE OF 99MTC-SESTAMIBI THYROID SCINTIGRAPHY WITH CALCULATION OF THYROID-TO-BACKGROUND RATIO IN PATIENTS WITH GRAVES' DISEASE, TOXIC MULTINODULAR GOITRE AND HYPOTHYROIDISMPattison, David, Westcott, James, Sivaratnam, Dinesh and Lichtenstein, Meir (2013). APPEARANCE OF 99MTC-SESTAMIBI THYROID SCINTIGRAPHY WITH CALCULATION OF THYROID-TO-BACKGROUND RATIO IN PATIENTS WITH GRAVES' DISEASE, TOXIC MULTINODULAR GOITRE AND HYPOTHYROIDISM. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Conference Publication ESTIMATION OF QUANTITATIVE THYROID-TO-BACKGROUND RATIO FOR Tc-99m-SESTAMIBI THYROID SCINTIGRAPHY IN PATIENTS WITH NORMAL THYROID FUNCTIONPattison, David, Westcott, James, Toh, Hock Boon, Lichtenstein, Meir and Sivaratnam, Dinesh (2013). ESTIMATION OF QUANTITATIVE THYROID-TO-BACKGROUND RATIO FOR Tc-99m-SESTAMIBI THYROID SCINTIGRAPHY IN PATIENTS WITH NORMAL THYROID FUNCTION. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Conference Publication QUANTITATIVE ASSESSMENT OF THYROID-TO-BACKGROUND RATIO IMPROVES THE INTER-OBSERVER RELIABILITY OF 99 m-Tc SESTAMIBI THYROID SCINTIGRAPHY FOR INVESTIGATION OF AMIODARONE-INDUCED THYROTOXICOSISPattison, David, Westcott, James, Lichtenstein, Meir, Toh, Hock Boon, Gunawardana, Dishan, Better, Nathan, Forehan, Simon and Sivaratnam, Dinesh (2013). QUANTITATIVE ASSESSMENT OF THYROID-TO-BACKGROUND RATIO IMPROVES THE INTER-OBSERVER RELIABILITY OF 99 m-Tc SESTAMIBI THYROID SCINTIGRAPHY FOR INVESTIGATION OF AMIODARONE-INDUCED THYROTOXICOSIS. HOBOKEN: WILEY-BLACKWELL. |
